0001520138-23-000131.txt : 20230313 0001520138-23-000131.hdr.sgml : 20230313 20230313171905 ACCESSION NUMBER: 0001520138-23-000131 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230312 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230313 DATE AS OF CHANGE: 20230313 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOVIE INC. CENTRAL INDEX KEY: 0001580149 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462510769 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39015 FILM NUMBER: 23728236 BUSINESS ADDRESS: STREET 1: 680 W NYE LANE STREET 2: SUITE 201 CITY: CARSON CITY STATE: NV ZIP: 89703 BUSINESS PHONE: 775-888-3162 MAIL ADDRESS: STREET 1: 680 W NYE LANE STREET 2: SUITE 201 CITY: CARSON CITY STATE: NV ZIP: 89703 FORMER COMPANY: FORMER CONFORMED NAME: NANOANTIBIOTICS, INC. DATE OF NAME CHANGE: 20130625 8-K 1 bivi-20230313_8k.htm CURRENT REPORT
0001580149 false --06-30 0001580149 2023-03-12 2023-03-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): March 12, 2023

 

BioVie Inc.
(Exact Name of Registrant as Specified in Its Charter)

 

Nevada   001-39015   46-2510769
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification No.)
         

680 W Nye Lane Suite 201

Carson City, NV

  89703
(Address of Principal Executive Offices)   (Zip Code)

 

(775) 888-3162

(Registrant’s Telephone Number, Including Area Code)

 

(Former Name or Former Address, if Changed Since Last Report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Class A Common Stock, par value $0.0001 per share BIVI The Nasdaq Stock Market, LLC

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On March 12, 2023, the board of directors of BioVie Inc. (the “Company”) approved and adopted the first amendment (the “First Amendment”) to the amended and restated bylaws of the Company (the “Bylaws”), which became effective immediately. The First Amendment amends the Bylaws to (i) provide each of the Chairman of the Board and the Chief Executive Officer with the authority to call a special meeting of the Board with no less than four hours prior notice and (ii) reduce the required number of directors on the Board from nine directors to no less than three nor more than eleven.

 

The foregoing description of the First Amendment is qualified by reference to the First Amendment, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

EXHIBIT INDEX

 

Exhibit No.   Description
3.1   First Amendment to the Amended and Restated Bylaws of BioVie Inc.
104   Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)
     

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BIOVIE INC.
     
  By:  /s/ Joanne Wendy Kim
  Name:  Joanne Wendy Kim
  Title: Chief Financial Officer

 

Date: March 13, 2023 

 

 

 

 

EX-3.1 2 bivi-20230313_8kex3z1.htm EXHIBIT 3.1

FIRST AMENDMENT TO

BYLAWS

OF

BIOVIE INC.

 

Adopted on March 12, 2023

_______________________________________________________

 

 

The Bylaws of BioVie Inc. (the “Corporation) are amended as follows:

 

Article III, Section 1 is amended in its entirety to read as follows:

 

Section 1. Number and Term. The number of directors of the Corporation shall be fixed as the Board of Directors may from time-to-time designate, provided that the number of members of the Board shall not be less than three (3) nor more than eleven (11). The number of authorized directors may be changed solely by action of the Board of Directors. No decrease in the number of directors shall have the effect of shortening the term of any incumbent director.

 

Article III, Section 8, third paragraph is deleted, and the following two paragraphs are substituted:

 

Regular meetings of the Board of Directors may be scheduled by a resolution by the Board. The Chairman of the Board or the President or the Secretary may call, and if requested by two directors, must call a special meeting of the Board of Directors. A special meeting of the Board of Directors may be called on oral or written notice to each director, given either personally or by telephone, United States mail, courier service, facsimile or e-mail Special meetings shall be called by the Chief Executive Officer, the President, or the Secretary in like manner and on like notice on the written request of two directors. Except as may be otherwise expressly provided by Nevada Revised Statutes, the Articles of Incorporation, or these Bylaws, neither the business to be transacted at, nor the purpose of, any special meeting need to be specified in a notice or waiver of notice.

 

Notice of time and place of a special meeting shall be given to each director (a) in a writing mailed not less than five (5) days before the date of such meeting or by overnight courier service sent not less than three (3) days before the date of such meeting addressed to the residence or usual place of business of a director as appears on the books and records of the Corporation; (b) by facsimile or email sent not less than two (2) days before the date of such meeting sent to the facsimile number or email address of a director as appears on the books and records of the Corporation; or (c) in person or by telephone delivered not less than two (2) days before the date of such meeting; provided, however, that if the Chairman of the Board or the Chief Executive Officer determines that it is otherwise necessary or advisable to hold the meeting sooner, the Chairman of the Board or the Chief Executive Officer, as the case may be, may prescribe a shorter notice to be given personally or by email, telephone, or facsimile provided that the notice shall be at least four (4) hours prior to the meeting. Attendance by a director at a meeting for which notice is required shall constitute a waiver of notice and a waiver of any and all objections to the date, time, place, or purpose of the meeting, or the manner in which it has been called or convened, except if the director states, at the beginning of the meeting or promptly upon arrival at the meeting, any objection to holding the meeting or to the transaction of business because the meeting is not lawfully called or convened and if the director, after objection, does not vote for or consent to any action taken at the meeting.

 

* * *

 

 -1-

 

 

CERTIFICATION

 

The undersigned hereby certifies that she is the duly elected, qualified, and acting Secretary of BioVie Inc., a Nevada corporation, and that the foregoing First Amendment to Bylaws was adopted as of the date hereof by the Corporation’s Board of Directors.

 

The undersigned has executed this Certificate as of March 12, 2023.

 

 

/s/ Joanne Wendy Kim

 

________________________

Joanne Wendy Kim

Secretary

 

 

 

 

 

 

 

 

 

 -2-

EX-101.SCH 3 bivi-20230312.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 bivi-20230312_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 bivi-20230312_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Mar. 12, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 12, 2023
Current Fiscal Year End Date --06-30
Entity File Number 001-39015
Entity Registrant Name BioVie Inc.
Entity Central Index Key 0001580149
Entity Tax Identification Number 46-2510769
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 680 W Nye Lane
Entity Address, Address Line Two Suite 201
Entity Address, City or Town Carson City
Entity Address, State or Province NV
Entity Address, Postal Zip Code 89703
City Area Code (775)
Local Phone Number 888-3162
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A Common Stock, par value $0.0001 per share
Trading Symbol BIVI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 bivi-20230313_8k_htm.xml IDEA: XBRL DOCUMENT 0001580149 2023-03-12 2023-03-12 iso4217:USD shares iso4217:USD shares 0001580149 false --06-30 8-K 2023-03-12 BioVie Inc. NV 001-39015 46-2510769 680 W Nye Lane Suite 201 Carson City NV 89703 (775) 888-3162 Class A Common Stock, par value $0.0001 per share BIVI NASDAQ false false false false false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://bioviepharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports bivi-20230313_8k.htm bivi-20230312.xsd bivi-20230312_lab.xml bivi-20230312_pre.xml bivi-20230313_8kex3z1.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bivi-20230313_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "bivi-20230313_8k.htm" ] }, "labelLink": { "local": [ "bivi-20230312_lab.xml" ] }, "presentationLink": { "local": [ "bivi-20230312_pre.xml" ] }, "schema": { "local": [ "bivi-20230312.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bivi", "nsuri": "http://bioviepharma.com/20230312", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "bivi-20230313_8k.htm", "contextRef": "From2023-03-12to2023-03-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://bioviepharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "bivi-20230313_8k.htm", "contextRef": "From2023-03-12to2023-03-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioviepharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001520138-23-000131-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001520138-23-000131-xbrl.zip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end